What is Vagistat-1 and how is it used?
Vagistat-1 is a prescription medicine used to treat the symptoms of Vaginal Candidiasis (Yeast Infection). Vagistat-1 may be used alone or with other medications.
Vagistat-1 belongs to a class of drugs called Antifungals, Vaginal.
It is not known if Vagistat-1 is safe and effective in children.
What are the possible side effects of Vagistat-1?
Vagistat-1 may cause serious side effects including:
- difficulty breathing, and
- swelling of your face, lips, tongue, or throat
Get medical help right away, if you have any of the symptoms listed above.
The most common side effects of Vagistat-1 include:
- vaginal redness or swelling,
- mild stomach pain,
- pain or burning when you urinate,
- runny or stuffy nose, and
- mild vaginal burning, itching or irritation after use
Tell the doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Vagistat-1. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
VAGISTAT-1 (tioconazole 6.5%) is formulated in a base of white, soft paraffin and aluminum magnesium silicate with butylated hydroxyanisole (BHA) added as a preservative. Each applicator-full of VAGISTAT-1 (tioconazole) provides approximately 4.6 grams of ointment containing 300 mg of tioconazole.
2 pharmacies near 91710 have coupons for 1-Day (Brand Names:Vagistat-1 for 4.5999999046325684GM of 6.5%)
Est. Regular Price
with free coupon
Est. Regular Price
with free coupon
VAGISTAT-1 (tioconazole) is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As VAGISTAT-1 (tioconazole) has been shown to be effective only for candidal vulvovaginitis, the diagnosis should be confirmed by KOH smears and/or cultures. Other pathogens commonly associated with vulvovaginitis should be ruled out by appropriate methods.
Studies have shown that women taking oral contraceptives have a cure rate similar to those not taking such agents when treated with VAGISTAT-1 (tioconazole) .
DOSAGE AND ADMINISTRATION
VAGISTAT-1 (tioconazole) has been found to be effective as a single- dose treatment for vulvovaginal candidiasis. Using the prefilled applicator, insert one applicator- full intravaginally. Administration of VAGISTAT-1 (tioconazole) just prior to bedtime may be preferred.
VAGISTAT-1 (tioconazole) is supplied in a ready-to-use, prefilled, single-dose vaginal applicator (NDC 0087-0657-40). Each applicator-full will deliver approximately 4.6 grams of VAGISTAT-1 containing 65 mg of tioconazole per gram of ointment.
Storage: Store at controlled room temperature 15°-30° C (59°-86° F).
The incidence of adverse reactions to VAGISTAT-1 (tioconazole) is based on clinical trials involving 1000 patients. Burning and itching were the most frequent side effects occurring in approximately 6% and 5% of the patients, respectively. In most instances these did not interfere with the course of therapy.
There were occasional reports (less than 1%) of other side effects including irritation, discharge, vulvar edema and swelling, vaginal pain, dysuria, nocturia, dyspareunia, dryness of vaginal secretions, desquamation, and burning sensation.
No information provided.
VAGISTAT-1 (tioconazole) is intended for intravaginal administration only. Applicators should be opened just prior to administration to prevent contamination. Administration of VAGISTAT-1 (tioconazole) just prior to bedtime may be preferred. The VAGISTAT-1 (tioconazole) ointment base may interact with rubber or latex products such as condoms or vaginal contraceptive diaphragms; therefore, use of such products within 72 hours following treatment is not recommended.
No long-term studies in animals have been performed to evaluate the carcinogenic potential of tioconazole.
Tioconazole did not demonstrate mutagenic activity at the levels examined in tests at either the chromosomal or subchromosomal level.
Impairment of Fertility
No impairment of fertility was seen in male rats administered tioconazole hydrochloride in oral doses up to 150 mg/kg/day. However, there was evidence of preimplantation loss in female rats at oral dose levels above 35 mg/kg/day.
Pregnancy Category C: Tioconazole hydrochloride had no adverse effects on fetal viability or growth when administered orally to pregnant rats at doses of 55, 110, and 165 mg/kg/day during the period of organogenesis. A drug- related increase in the incidence of dilated ureters, hydroureters, and hydronephrosis observed in the fetuses of this study was transient and no longer evident in pigs raised to 21 days of age. These effects did not occur following intravaginal administration of approximately 10 mg/kg/day in a 2% cream. There was no evidence of major structural anomalies. No embryotoxic or teratogenic effects were observed in rabbits receiving oral dose levels as high as 165 mg/kg/day or daily intravaginal application of approximately 2-3 mg/kg in a 2% tioconazole cream during organogenesis. Tioconazole hydrochloride, like other azole antimycotic agents, causes dystocia in rats when treatment is extended through parturition. Associated effects in rats include prolongation of pregnancy, in utero deaths, and impaired pup survival. The ''no-effect'' level for this phenomenon is 20 mg/kg/day orally and approximately 9 mg/kg/day intravaginally. No effect on parturition occurred in rabbits at 50 mg/kg/day orally.
There are no adequate and well-controlled studies in pregnant women. VAGISTAT® -1 (tioconazole 6.5%) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, nursing should be temporarily discontinued while VAGISTAT-1 (tioconazole) is administered.
Safety and effectiveness in children have not been established.
Tioconazole is a broad-spectrum antifungal agent that inhibits the growth of human pathogenic yeasts. Tioconazole exhibits fungicidal activity in vitro against Candida albicans, other species of the genus Candida, and against Torulopsis glabrata.
The VAGISTAT-1 (tioconazole) ointment base may interact with rubber or latex products such as condoms or vaginal contraceptive diaphragms; therefore, use of such products within 72 hours following treatment is not recommended.
Women's Conditions Resources
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors